Voyager Therapeutics, Inc.
Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
About
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Employees
162
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
75 Hayden Avenue, Lexington, MA 02421, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 13, 2025 | — | — | — | — |
| Feb 27, 2025 | — | — | — | — |
| Nov 13, 2024 | -0.45 | -0.16 | 0.29 | -64.44% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 8 | — | 10 |
| Average estimate | — | -0.44 | — | -1.49 |
| Low estimate | — | -0.72 | — | -3.08 |
| High estimate | — | -0.17 | — | -0.63 |
| Last year EPS | — | -0.20 | — | -0.91 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-128.030%
Next qtr. (Mar 2025)
-119.100%
Current year
-130.740%
Next year (Dec 2025)
-63.200%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 250.01M | 40.91M | 37.42M | 171.13M | 104.39M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 92.17M | 60.76M | 73.79M | 108.75M | 119.74M |
| Selling general and admin | 35.82M | 30.98M | 37.25M | 34.99M | 36.34M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 122.01M | -50.84M | -73.62M | 27.38M | -51.68M |
| Non operating interest income | |||||
| Income | — | — | — | 1.66M | 6.46M |
| Expense | — | — | — | — | — |
| Other income expense | 3,000 | 2.65M | 2.81M | 7.70M | 1.63M |
| Pretax income | 133.74M | -46.39M | -71.20M | 36.74M | -43.60M |
| Tax provision | 1.41M | 16,000 | — | — | — |
| Net income | 132.33M | -46.41M | -71.20M | 36.74M | -43.60M |
| Basic EPS | 3.08 | -1.21 | -1.89 | 0.99 | -1.21 |
| Diluted EPS | 2.97 | -1.21 | -1.89 | 0.98 | -1.21 |
| Basic average shares | 43.02M | 38.36M | 37.67M | 37.13M | 35.90M |
| Diluted average shares | 43.02M | 38.36M | 37.67M | 37.13M | 35.90M |
| EBITDA | 126.46M | -44.65M | -68.45M | 31.20M | -48.91M |
| Net income from continuing op. | 132.33M | -46.41M | -71.20M | 36.74M | -43.60M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 351.28M | 159.36M | 193.86M | 261.58M | 354.76M |
| Current assets | |||||
| Cash | 3.21M | 7.24M | — | — | — |
| Cash equivalents | 65.59M | 91.72M | — | — | — |
| Cash and cash equivalents | 68.80M | 98.96M | 117.43M | 104.44M | 86.04M |
| Other short term investments | 162.07M | 19.89M | 15.11M | 76.70M | 195.49M |
| Accounts receivable | 80.15M | — | 732,000 | 8.01M | 18.50M |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 1.73M | 779,000 | 1.71M | 3.13M | 2.20M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | 3.82M | 554,000 |
| Other current assets | 2.63M | 4.23M | 1.70M | 1.58M | 1.40M |
| Non current assets | |||||
| Properties | 35.31M | 35.66M | 53.07M | 54.32M | 42.91M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 2.63M | 2.33M | 2.52M | 2.41M | 1.89M |
| Construction in progress | — | — | — | 866,000 | 2.19M |
| Leases | 7.11M | 12.55M | 15.70M | 15.47M | 7.13M |
| Accumulated depreciation | -15.04M | -17.21M | -15.91M | -11.57M | -7.66M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | 1.92M |
| Other non current assets | 1.59M | 1.52M | 1.78M | 2.32M | 1.72M |
| Total liabilities | 114.96M | 100.34M | 98.80M | 107.26M | 255.25M |
| Current liabilities | |||||
| Accounts payable | 1.60M | 2.57M | 574,000 | 634,000 | 4.07M |
| Accrued expenses | 10.21M | 3.26M | 5.93M | 8.35M | 15.78M |
| Short term debt | 3.20M | 2.83M | 5.57M | 4.20M | 3.19M |
| Deferred revenue | 42.88M | 59.38M | 33.89M | 7.73M | 47.23M |
| Tax payable | — | — | — | — | — |
| Pensions | 6.61M | 4.56M | 5.02M | 5.86M | 5.73M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 17.09M | 20.29M | 38.61M | 43.41M | 30.98M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Shareholders equity | |||||
| Common stock | 44,000 | 38,000 | 38,000 | 37,000 | 37,000 |
| Retained earnings | -261.18M | -393.51M | -347.10M | -275.91M | -312.65M |
| Other shareholders equity | -48,000 | -219,000 | -138,000 | -134,000 | -104,000 |
| Total shareholders equity | 236.32M | 59.02M | 95.06M | 154.32M | 99.51M |
| Additional paid in capital | 497.51M | 452.71M | 442.26M | 430.32M | 412.23M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | 132.33M | -46.41M | -71.20M | 36.74M | -43.60M | -88.29M | -70.70M | -40.19M | -29.67M | -16.32M |
| Depreciation | 4.44M | 6.19M | 5.17M | 3.82M | 2.77M | 2.12M | 1.60M | 612,000 | 600,000 | 184,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 11.15M | 9.34M | 11.32M | 14.93M | 15.64M | 15.71M | 9.24M | 6.31M | 4.03M | 425,000 |
| Other Non-Cash Items | — | -2.47M | -2.46M | -7.70M | -996,000 | 1.30M | 674,000 | 2.94M | 11.79M | 3.66M |
| Accounts Receivable | -83.23M | 475,000 | 7.28M | 10.48M | -18.50M | — | — | — | — | — |
| Accounts Payable | -962,000 | 1.99M | -60,000 | -3.44M | 2.60M | -282,000 | 470,000 | -62,000 | -942,000 | 604,000 |
| Other Assets & Liabilities | 8.56M | 23.12M | -2.47M | -144.55M | 80.93M | 61.25M | -9.14M | -14.58M | 52.49M | 521,000 |
| Operating Cash Flow | 72.28M | -7.76M | -52.42M | -89.71M | 38.85M | -8.19M | -67.86M | -44.97M | 38.29M | -10.93M |
| Investing Activities | ||||||||||
| Capital Expenditures | -3.26M | -2.49M | -1.61M | -12.10M | -7.55M | -4.31M | -3.99M | -5.03M | -1.03M | -2.99M |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -223.97M | -54.85M | -15.12M | -70.40M | -494.23M | -333.23M | -147.30M | -112.35M | -220.40M | — |
| Sale of Investments | 85.58M | 50.00M | 82.63M | 195.50M | 411.30M | 364.00M | 147.60M | 165.10M | 26.66M | — |
| Investing Cash Flow | -141.64M | -7.34M | 65.91M | 113.00M | -90.48M | 26.47M | -3.68M | 47.30M | -194.77M | -3.30M |
| Financing Activities | ||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | 31.12M | — | — | — | 77.62M | — | 57.99M | — | 104.78M | 22.04M |
| Other Cash Details | ||||||||||
| End Cash Position | 70.40M | 100.47M | 119.21M | 106.22M | 86.78M | 47.59M | 32.27M | 37.38M | 31.31M | 7.04M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 74.66M | -15.00M | -55.13M | -108.81M | 40.95M | -20.19M | -65.34M | -47.51M | 40.27M | -14.91M |
Error: Invalid format in Holders JSON file.
Article
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data. VY7523, a monoclonal antibody for early Alzheimer's treatment, is expected to yield Phase I results by mid-2025, with potential undervaluation of VYGR shares. The competitive landscape includes Denali, Roche, and AbbVie, with varying BBB-crossing strategies, highlighting the speculative nature of investing in early-stage neurological therapies.
Jan 30, 2025
Article
What Makes Voyager Therapeutics (VYGR) a New Buy Stock
Voyager Therapeutics (VYGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jan 30, 2025
Article
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
Dec 17, 2024
